GO:2000209 regulation of anoikis: Cell Death Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000209 (regulation of anoikis) describes any process that modulates the frequency, rate or extent of anoikis, the detachment-induced programmed cell death that occurs when cells lose integrin-mediated attachment to the extracellular matrix.
• Anoikis is executed through both intrinsic mitochondrial and extrinsic death receptor pathways, with Bcl-2 family proteins acting as central rheostats of cell survival versus death after matrix detachment.
• Cancer cells frequently acquire anoikis resistance, a hallmark that enables anchorage-independent survival, dissemination and metastatic colonization.
• Noncoding RNAs including microRNAs and long noncoding RNAs are major post-transcriptional regulators of anoikis and anchorage-independent growth.
• Transcription factors such as TCF7L2 and cytoskeletal proteins such as TUBB3 can directly promote anoikis resistance and metastasis, making them candidate therapeutic targets.
• CRISPR knockout, point-mutation, knock-in and overexpression models combined with library screening provide causal evidence for how individual genes regulate anoikis.
Description
Anoikis is a specialized form of programmed cell death triggered when adherent cells detach from the extracellular matrix or from neighboring cells. The Gene Ontology term GO:2000209, regulation of anoikis, captures all biological processes that modulate the frequency, rate or extent of this detachment-induced cell death. Because anoikis acts as a physiological barrier against ectopic cell survival, its dysregulation is directly linked to cancer progression, metastasis and tissue remodeling. Understanding which genes and pathways regulate anoikis is therefore central to both basic cell biology and translational oncology. Mechanistically, regulation of anoikis integrates signals from integrins, growth factor receptors, death receptors and the Bcl-2 family of apoptosis regulators. Loss of matrix attachment alters these signaling networks and shifts the balance between pro-survival and pro-death effectors, determining whether a detached cell dies or survives. Extrinsic death receptor pathways, including Fas and TRAIL receptor signaling, can also directly modulate anoikis sensitivity. In parallel, noncoding RNAs fine-tune the expression of anoikis regulators, adding layers of post-transcriptional control. For researchers, GO:2000209 provides a structured framework to annotate genes, interpret transcriptomic and proteomic data, and design functional experiments. Because anoikis resistance is a hallmark of metastatic cancer, interventions that restore anoikis sensitivity are actively pursued as therapeutic strategies. This article summarizes the definition, core mechanisms, key genes, disease links and experimental methods relevant to regulation of anoikis, with all statements grounded in published literature.
regulation of anoikis At A Glance
| GO ID | GO:2000209 |
|---|---|
| GO term | regulation of anoikis |
| Ontology | biological_process |
| Synonym | regulation of detachment induced cell death; regulation of suspension induced apoptosis |
| Definition | Any process that modulates the frequency, rate or extent of anoikis. |
| Major function | Controls whether matrix-detached cells survive or die, thereby influencing tissue homeostasis and metastasis. |
| Key molecular players | Integrins, growth factor receptors, death receptors, Bcl-2 family proteins, noncoding RNAs, transcription factors. |
| Disease relevance | Cancer metastasis, anoikis resistance, tissue remodeling disorders. |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, RNA-seq, proteomics, anoikis assays, library screening. |
What Is GO:2000209?
GO:2000209, regulation of anoikis, is a biological process term defined as any process that modulates the frequency, rate or extent of anoikis. In other words, it encompasses all molecular and cellular events that make a detached cell more or less likely to undergo detachment-induced cell death. This includes signaling through integrins and growth factor receptors, regulation of Bcl-2 family proteins, death receptor pathways, transcriptional and post-transcriptional control, and any other mechanism that quantitatively or qualitatively changes the anoikis response.
Why Is regulation of anoikis Important in Cell Biology?
Regulation of anoikis is fundamentally important because it determines the fate of cells that lose their normal matrix attachments. In healthy tissues, anoikis prevents detached cells from surviving in inappropriate locations, acting as a tumor-suppressive barrier. In cancer, however, acquired anoikis resistance allows cells to survive during detachment, travel through the circulation and colonize distant organs, making it a critical step in metastasis. Consequently, genes and pathways that regulate anoikis are attractive targets for anti-metastatic therapy, and understanding their mechanisms is essential for developing new treatments.
• Anoikis is a physiological safeguard against ectopic cell survival and is dysregulated in many cancers.
• Anoikis resistance is a hallmark of metastatic cancer cells and enables anchorage-independent growth.
• Bcl-2 family proteins integrate pro-survival and pro-death signals during anoikis, making them key effectors.
• Extrinsic death receptor pathways provide an additional layer of anoikis regulation.
• Noncoding RNAs regulate anoikis and anchorage-independent growth, offering new therapeutic targets.
• Transcription factors such as TCF7L2 can promote anoikis resistance and metastasis by activating specific target genes.
• Cytoskeletal proteins such as TUBB3 modulate anoikis resistance and bone metastasis in prostate cancer.
• PDGFR-integrin interactions regulate anoikis resistance in glioblastoma progression.
• Targeting anoikis resistance is a promising strategy for cancer therapy.
• CRISPR-based models enable causal testing of candidate anoikis regulators.
What Happens During regulation of anoikis?
Loss of matrix attachment and integrin signaling
In simple terms: When a cell loses its grip on the surrounding matrix, integrin signals change and can trigger a death program.
Anoikis is initiated when cells detach from the extracellular matrix, leading to altered integrin clustering and signaling. Integrins normally provide survival signals; their loss upon detachment contributes to the activation of the anoikis program. PDGFR-integrin interactions have been shown to modulate anoikis resistance in glioblastoma, indicating that crosstalk between growth factor receptors and integrins is a key regulatory node.
Intrinsic mitochondrial pathway and Bcl-2 family regulation
In simple terms: The mitochondria decide whether the detached cell lives or dies, and Bcl-2 proteins are the decision-makers.
The intrinsic apoptotic pathway is a major route for anoikis. Bcl-2 family proteins, including pro-survival and pro-apoptotic members, are regulated during anoikis and amorphosis, shifting the balance toward mitochondrial outer membrane permeabilization and caspase activation when detachment occurs. This regulation is central to determining the cell's fate after matrix loss.
Extrinsic death receptor pathways
In simple terms: Death receptors on the cell surface can also directly instruct a detached cell to die.
Extrinsic death receptor pathways, such as those involving Fas and TRAIL receptors, regulate anoikis by transmitting pro-death signals from the environment. These pathways can cooperate with or override intrinsic survival cues, adding another layer of control over detachment-induced cell death.
Transcriptional and post-transcriptional control
In simple terms: Genes and RNAs can be switched on or off to make cells more or less sensitive to anoikis.
Transcription factors such as TCF7L2 promote anoikis resistance by transcriptionally activating target genes like PLAUR, linking transcriptional programs to metastatic behavior. Noncoding RNAs, including microRNAs and long noncoding RNAs, also regulate anoikis and anchorage-independent growth, often by targeting multiple components of the anoikis machinery.
Cytoskeletal and structural determinants
In simple terms: The cell's internal skeleton helps decide whether detachment leads to death.
Cytoskeletal proteins such as TUBB3 contribute to anoikis resistance; targeting TUBB3 suppresses anoikis resistance and bone metastasis in prostate cancer. This highlights that structural and cytoskeletal dynamics are integral to the regulation of anoikis.
Key Genes Involved in GO:2000209 regulation of anoikis
The following genes and proteins have been experimentally implicated in the regulation of anoikis, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| BCL2 | Pro-survival Bcl-2 family protein; inhibits mitochondrial apoptosis | Central regulator of anoikis; target for sensitizing cells to detachment |
| BAX | Pro-apoptotic Bcl-2 family effector; promotes mitochondrial permeabilization | Key executor of intrinsic anoikis; studied in detachment models |
| BAK | Pro-apoptotic Bcl-2 family effector; mediates MOMP | Cooperates with BAX in anoikis; relevant for resistance mechanisms |
| FAS | Death receptor; triggers extrinsic apoptosis | Regulates anoikis via extrinsic pathway |
| TNFRSF10A/B (TRAIL receptors) | Death receptors for TRAIL; activate caspase-8 | Modulate anoikis sensitivity in cancer cells |
| TCF7L2 | Transcription factor; activates PLAUR and other targets | Promotes anoikis resistance and metastasis in gastric cancer |
| PLAUR (uPAR) | Plasminogen activator receptor; cell adhesion and migration | Transcriptional target of TCF7L2; supports anoikis resistance |
| TUBB3 | Beta-tubulin isotype; cytoskeletal component | Targeting TUBB3 suppresses anoikis resistance and bone metastasis |
| PDGFRA/B | Growth factor receptors; interact with integrins | PDGFR-integrin crosstalk regulates anoikis resistance in glioblastoma |
| ITGB1 (Integrin beta 1) | Matrix adhesion receptor; mediates survival signaling | Loss of integrin signaling upon detachment contributes to anoikis |
| ITGB3 (Integrin beta 3) | Matrix adhesion receptor; interacts with PDGFR | Involved in PDGFR-integrin regulation of anoikis resistance |
| MIRNAs (e.g., miR-21, miR-30a) | Noncoding RNAs; post-transcriptional regulators | Regulate anoikis and anchorage-independent growth |
| LncRNAs (e.g., MALAT1, HOTAIR) | Long noncoding RNAs; modulate gene expression | Implicated in anoikis regulation and cancer progression |
| CASP8 | Initiator caspase for extrinsic apoptosis | Mediates death receptor-induced anoikis |
| CASP3 | Executioner caspase | Final effector of anoikis cell death |
| BID | BH3-only protein; links extrinsic and intrinsic pathways | Amplifies death receptor signals during anoikis |
| BMF | BH3-only protein; regulated by detachment | Contributes to anoikis induction upon matrix loss |
| PUM1/2 | RNA-binding proteins; post-transcriptional regulators | Modulate anoikis-related gene expression |
How Is regulation of anoikis Regulated?
Regulation of anoikis is controlled at multiple levels. Extrinsic death receptor pathways, including Fas and TRAIL receptor signaling, directly modulate anoikis sensitivity. Bcl-2 family proteins integrate survival and death signals downstream of detachment, with their balance determining mitochondrial outer membrane permeabilization. Growth factor receptor signaling, such as PDGFR-integrin crosstalk, can promote anoikis resistance in cancer cells. Transcription factors like TCF7L2 activate pro-survival target genes such as PLAUR to confer anoikis resistance. Noncoding RNAs provide an additional post-transcriptional layer of regulation, influencing anchorage-independent growth. Together, these mechanisms fine-tune the decision between survival and death after matrix detachment.
regulation of anoikis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TCF7L2 | Gastric cancer metastasis and anoikis resistance | Knockout or overexpression in gastric cancer cell lines; anoikis assays |
| PLAUR | Gastric cancer metastasis; downstream of TCF7L2 | Knockdown or knockout in gastric cancer cells; detachment assays |
| TUBB3 | Prostate cancer bone metastasis and anoikis resistance | Knockout or point mutation in prostate cancer cells; bone metastasis models |
| PDGFRA/B | Glioblastoma progression and anoikis resistance | Knockout or knock-in in glioblastoma cells; integrin crosstalk studies |
| BCL2 | Anoikis resistance in multiple cancers | Overexpression or point mutation in cancer cell lines; mitochondrial apoptosis assays |
Cancer metastasis and anoikis resistance
Anoikis resistance is a critical step in the metastatic cascade, allowing cancer cells to survive after detachment from the primary tumor, travel through the bloodstream and colonize distant organs. Many cancers acquire anoikis resistance through upregulation of pro-survival Bcl-2 family proteins, activation of growth factor receptor signaling, or transcriptional reprogramming. Targeting anoikis resistance has therefore emerged as a promising therapeutic strategy for cancer.
Gastric cancer and TCF7L2-PLAUR axis
In gastric cancer, the transcription factor TCF7L2 promotes anoikis resistance and metastasis by transcriptionally activating PLAUR. This axis illustrates how a specific transcriptional program can drive anchorage-independent survival and metastatic spread, providing candidate targets for intervention.
Prostate cancer bone metastasis and TUBB3
In prostate cancer, the cytoskeletal protein TUBB3 supports anoikis resistance and bone metastasis; targeting TUBB3 suppresses these phenotypes. This demonstrates that structural proteins can be critical regulators of anoikis and metastatic colonization in bone.
Glioblastoma progression and PDGFR-integrin crosstalk
In glioblastoma, PDGFR-integrin interactions regulate anoikis resistance and contribute to tumor progression. This highlights the importance of microenvironmental signaling crosstalk in modulating anoikis in brain tumors.
From regulation of anoikis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for anoikis regulation? | CRISPR knockout cell line followed by detachment-induced anoikis assays |
| Does a specific point mutation alter anoikis sensitivity? | CRISPR point-mutation knock-in of the mutation; compare anoikis rates |
| Does a candidate gene promote anoikis resistance? | CRISPR overexpression or knock-in of the gene; anchorage-independent growth assays |
| What is the role of a noncoding RNA in anoikis? | CRISPR knockout or overexpression of the noncoding RNA locus; RNA-seq and anoikis assays |
| Which genes regulate anoikis in a genome-wide manner? | CRISPR library screening under detachment conditions; bioinformatics analysis |
| Does a transcription factor directly regulate anoikis genes? | Knock-in of tagged transcription factor; ChIP-seq and anoikis assays |
How to Study the regulation of anoikis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Suspension culture anoikis assay | Cell viability and caspase activation after detachment | Functional validation of anoikis regulators |
| RNA-seq | Transcriptome changes during detachment or in resistant cells | Discovery of coding and noncoding regulators |
| Proteomics | Protein expression and modification changes | Quantifying Bcl-2 family and death receptor proteins |
| CRISPR knockout screening | Genes required for anoikis or anoikis resistance | Genome-wide discovery of regulators |
| CRISPR activation (CRISPRa) screening | Genes whose overexpression confers anoikis resistance | Identifying pro-survival factors |
| ChIP-seq | Transcription factor binding sites | Mapping TCF7L2 targets in anoikis resistance |
| Anchorage-independent growth assay | Colony formation in soft agar or suspension | Measuring anoikis resistance phenotype |
| Immunoblotting | Protein cleavage and expression | Detecting caspase activation and Bcl-2 family changes |
Anoikis assays and detachment models
Anoikis is commonly studied by culturing cells in suspension or on poly-HEMA-coated plates to prevent attachment, followed by viability or caspase activity measurements. These assays directly quantify the frequency of detachment-induced cell death and are the gold standard for functional studies.
Transcriptomics and RNA-seq
RNA-seq can identify genes and noncoding RNAs whose expression changes during detachment or in anoikis-resistant cells. Comparing attached versus detached conditions reveals candidate regulators of anoikis.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics can quantify changes in Bcl-2 family proteins, death receptor components and signaling intermediates during anoikis. Phosphoproteomics can reveal kinase pathways that modulate anoikis sensitivity.
CRISPR screening and bioinformatics
Genome-wide CRISPR knockout or activation screens under detachment conditions can identify genes that regulate anoikis. Bioinformatics analysis of screen hits, combined with pathway enrichment, helps prioritize candidates for validation.
How CRISPR Can Be Used to Study GO:2000209 regulation of anoikis
Knockout
CRISPR knockout of candidate genes is used to test whether they are required for regulation of anoikis. For example, knocking out TCF7L2 or PLAUR can reduce anoikis resistance in gastric cancer cells. Knockout of Bcl-2 family members can sensitize cells to detachment-induced death.
Point Mutation
CRISPR point mutation can introduce specific amino acid changes to test the function of individual residues in anoikis regulators. This is particularly useful for dissecting phosphorylation sites or interaction domains in proteins such as Bcl-2 family members or death receptors.
Knock-in
Knock-in of tagged or reporter alleles allows visualization and quantification of anoikis regulators in live cells. For example, knocking in a fluorescent tag on a caspase or Bcl-2 family protein enables real-time monitoring of anoikis.
Overexpression
CRISPR overexpression (e.g., CRISPRa) can test whether increased expression of a candidate gene is sufficient to confer anoikis resistance. Overexpression of TCF7L2 or PLAUR promotes anoikis resistance and metastasis in models. Overexpression of pro-survival Bcl-2 proteins also blocks anoikis.
How EDITGENE Supports regulation of anoikis Research
Researchers studying regulation of anoikis-related genes often need to determine whether a candidate gene is causally involved in detachment-induced cell death or anoikis resistance. CRISPR-based models provide the necessary causal evidence, and EDITGENE offers a comprehensive suite of services to generate and characterize such models.
Contact EDITGENE today to design your custom CRISPR model for regulation of anoikis research.
Frequently Asked Questions About regulation of anoikis
What is regulation of anoikis (GO:2000209)?
GO:2000209 is a Gene Ontology biological process term defined as any process that modulates the frequency, rate or extent of anoikis, the detachment-induced programmed cell death.
What genes are involved in regulation of anoikis?
Key genes include BCL2, BAX, BAK, FAS, TNFRSF10A/B, TCF7L2, PLAUR, TUBB3, PDGFRA/B, ITGB1, ITGB3, CASP8, CASP3, BID and BMF, as well as noncoding RNAs.
How is anoikis regulated in cancer?
Cancer cells often acquire anoikis resistance through upregulation of pro-survival Bcl-2 proteins, activation of growth factor receptor signaling, transcriptional reprogramming and noncoding RNA networks.
What is the role of Bcl-2 proteins in anoikis?
Bcl-2 family proteins integrate survival and death signals after matrix detachment, determining whether mitochondrial outer membrane permeabilization and apoptosis proceed.
How do death receptors regulate anoikis?
Extrinsic death receptor pathways, including Fas and TRAIL receptor signaling, can directly transmit pro-death signals that modulate anoikis sensitivity.
What is the role of noncoding RNAs in anoikis?
Noncoding RNAs, including microRNAs and long noncoding RNAs, regulate anoikis and anchorage-independent growth by post-transcriptionally controlling anoikis-related genes.
How can I study regulation of anoikis in the lab?
Common methods include suspension culture anoikis assays, RNA-seq, proteomics, CRISPR knockout or overexpression, and genome-wide CRISPR screening.
What is anoikis resistance?
Anoikis resistance is the ability of cells to survive after detachment from the extracellular matrix, a hallmark of metastatic cancer cells.
Which diseases are linked to dysregulated anoikis?
Dysregulated anoikis is linked to cancer metastasis, including gastric cancer, prostate cancer bone metastasis and glioblastoma progression.
How does TCF7L2 regulate anoikis?
TCF7L2 promotes anoikis resistance and metastasis by transcriptionally activating PLAUR in gastric cancer.
Conclusion
Regulation of anoikis (GO:2000209) is a fundamental biological process that determines cell fate after matrix detachment. Its dysregulation contributes to cancer metastasis and other pathologies, making it a key area of research. Understanding the molecular players, from Bcl-2 family proteins and death receptors to transcription factors and noncoding RNAs, provides a foundation for therapeutic targeting. CRISPR-based models and screening approaches are powerful tools to dissect these mechanisms and identify new intervention points.
References
- 1. Han YH et al.. 2023. Regulation of anoikis by extrinsic death receptor pathways.. Cell Commun Signal 21(1):227 PMID: 37667281
- 2. Lee HY et al.. 2021. The Role of Noncoding RNAs in the Regulation of Anoikis and Anchorage-Independent Growth in Cancer.. Int J Mol Sci 22(2) PMID: 33435156
- 3. Zhang T et al.. 2022. TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR.. Int J Biol Sci 18(11):4560-4577 PMID: 35864968
- 4. Wang Y et al.. 2024. Targeting anoikis resistance as a strategy for cancer therapy.. Drug Resist Updat 75:101099 PMID: 38850692
- 5. Martin SS et al.. 2004. Regulation of Bcl-2 proteins during anoikis and amorphosis.. Biochim Biophys Acta 1692(2-3):145-57 PMID: 15246684
- 6. Pain P et al.. 2025. Involvement of PDGFR-integrin interactions in the regulation of anoikis resistance in glioblastoma progression.. Cell Biol Int 49(1):3-15 PMID: 39523497
- 7. Su H et al.. 2013. [The regulation of anoikis in tumor invasion and metastasis].. Yi Chuan 35(1):10-6 PMID: 23357260
- 8. Dong B et al.. 2024. Targeting TUBB3 Suppresses Anoikis Resistance and Bone Metastasis in Prostate Cancer.. Adv Healthc Mater 13(28):e2400673 PMID: 38809199
